The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

Claims 1-22. (Cancelled).

23. (New) A method of administering a pharmaceutically effective dose of aerosolized tetrahydrocannabinol to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said tetrahydrocannabinol in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said tetrahydrocannabinol, wherein at least 20% of the mass of said respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

24. (New) The method of claim 23 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.

25. (New) The method of claim 23 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.

26. (New) The method of claim 23 wherein said pharmaceutically acceptable solvent comprises ethanol.

27. (New) The method of claim 23 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.

28. (New) The method of claim 23 wherein said solution is surfactant free.

29. (New) The method of claim 23 wherein said tetrahydrocannabinol is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.

30. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat nausea.

31. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat vomiting.

32. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to reduce pain.

33. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve muscle spasticity.

34. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve migraine headaches.

35. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve movement disorders.

36. (New) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to increase appetite in patients suffering from cachexia.

37. (New) A method of administering a pharmaceutically effective dose of medical marijuana to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said medical marijuana in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically

acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said medical marijuana, wherein at least 20% of the mass of the respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

38. (New) The method of claim 37 wherein said pharmaceutically acceptable solvent comprises ethanol.

39. (New) The method of claim 37 wherein said solution consists essentially of said hydrofluoroalkane and said medical marijuana.

40. (New) The method of claim 37 wherein said solution is surfactant free.

41. (New) The method of claim 37 wherein said medical marijuana is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.

42. (New) The method of claim 37 wherein said pharmaceutically effective dose is sufficient to treat a condition selected from the group consisting of nausea, vomiting, pain, muscle spasticity, migraine headaches, movement disorders, and loss of appetite due to cachexia.

43.(New) A pharmaceutical composition comprising a hydrofluoroalkane, Δ^9-tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said Δ^9-tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said Δ^9-tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (±0.008) to 5.940% w/w (±0.191).

44. (New) The pharmaceutical composition of claim 43 wherein said Δ^9-tetrahydrocannabinol is present in pharmaceutically pure form.

45. (New) The method of claim 43 wherein said Δ^9-tetrahydrocannabinol is a pharmaceutically acceptable salt of said Δ^9-tetrahydrocannabinol .

46. (New) The pharmaceutical composition of claim 43 wherein said organic solvent comprises ethanol.

47. (New) The pharmaceutical composition of claim 43 wherein said solution consists essentially of said hydrofluoroalkane and said Δ^9-tetrahydrocannabinol.

48. (New) The pharmaceutical composition of claim 43 wherein said stable composition is surfactant free.

49. (New) The pharmaceutical composition of claim 43 wherein said Δ^9-tetrahydrocannabniol is present in said stable composition at a concentration sufficient to achieve serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.

50. (New) A pharmaceutical composition comprising a hydrofluoroalkane, a tetrahydrocannabinol , and up to 15 percent by weight of an organic solvent, said tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (±0.008) to 5.940% w/w (±0.191).

51. (New) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.

52. (New) The method of claim 50 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.

53. (New) The pharmaceutical composition of claim 50 wherein said organic solvent comprises ethanol.

54. (New) The pharmaceutical composition of claim 50 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.

55. (New) The pharmaceutical composition of claim 50 wherein said stable composition is surfactant free.

56. (New) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in said stable composition at a concentration sufficient to achieve serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.